APOE and Alzheimer disease: These existing studies, including work by Thambisetty and Reiman, have helped to show ApoE ε4 dose-dependent associations between cerebral blood flow decline and hypometabolism, both validated readouts of AD (Reiman et al., 1996; Thambisetty et al., 2010a).